Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
J Urol. 2018 May;199(5):1224-1232. doi: 10.1016/j.juro.2017.10.044. Epub 2017 Nov 9.
Data on the incidence, mortality and burden of prostate cancer as well as changing trends are necessary to provide policy makers with the evidence needed to allocate resources appropriately. This study presents estimates of prostate cancer incidence, mortality and burden from 1990 to 2015 by patient age, country and developmental status using the results of the Global Burden of Disease 2015 study.
Data from vital registration systems and cancer registries were used to generate mortality estimates. Cause specific mortality served as the basis for estimating incidence, prevalence and disability adjusted life years. The global number of incident cases, deaths and disability adjusted life years attributable to prostate cancer are reported as well as age standardized rates.
Incident cases of prostate cancer increased 3.7-fold from 1990 to 2015. The age standardized incidence rate also increased 1.7-fold during the study period and in 2015 it reached 56.71/100,000 person-years (95% uncertainty interval 45.86-78.45). Global estimates of the age standardized death rate decreased slightly to 14.24 deaths (95% uncertainty interval 11.8-17.95) per 100,000 person-years in 2015. The decline in the age standardized death rate was more prominent in high income countries. Disability adjusted life years attributable to prostate cancer increased by 90% during the study period.
The prostate cancer mortality rate is decreasing in high income countries. However, the incidence and burden of disease are steadily increasing globally, resulting in further challenges in the allocation of limited health care resources. The current study provides comprehensive knowledge of the local burden of disease and help with appropriate allocation of resources for prostate cancer prevention, screening and treatment.
提供前列腺癌的发病率、死亡率和负担数据以及变化趋势,为决策者提供适当分配资源所需的证据。本研究利用 2015 年全球疾病负担研究的结果,按患者年龄、国家和发展状况,估算了 1990 年至 2015 年前列腺癌的发病率、死亡率和负担。
使用生命登记系统和癌症登记处的数据来生成死亡率估计值。特定病因死亡率是估计发病率、患病率和伤残调整生命年的基础。报告了全球前列腺癌新发病例、死亡人数和伤残调整生命年以及年龄标准化率。
1990 年至 2015 年,前列腺癌新发病例增加了 3.7 倍。研究期间,年龄标准化发病率也增加了 1.7 倍,2015 年达到 56.71/100,000人年(95%不确定区间为 45.86-78.45)。2015 年,全球年龄标准化死亡率估计值略有下降,至每 100,000 人年 14.24 人(95%不确定区间为 11.8-17.95)。高收入国家年龄标准化死亡率下降更为明显。2015 年,归因于前列腺癌的伤残调整生命年增加了 90%。
在高收入国家,前列腺癌死亡率正在下降。然而,全球的发病率和疾病负担在稳步增加,这给有限的卫生保健资源的分配带来了进一步的挑战。本研究提供了关于当地疾病负担的综合知识,有助于为前列腺癌的预防、筛查和治疗合理分配资源。